ALK-Abelló A/S

ALK-B · Nasdaq Copenhagen · Healthcare

201.60DKK +2.1%last day

Price as of 2 October 2026

The price over the past year, with dividends: −1.2%

Performance

1 month

−3.6%

1 year

−1.2%

3 years, per year

+34.7%

5 years, per year

+7.0%

Largest fall, 3 years

−56.6%

Below the peak now

−25.4%

Volatility, 1 year

27.1%

Return with dividends reinvested.

Key figures

P/E

32.5

P/B

6.4

Dividend yield

0.8%

Return on equity

+19.5%

Net margin

+19.9%

Market value

6.7 bn USD

Quality, value and trend

Where ALK-Abelló stands against every Nordic stock today. 100 is best.

Quality97

Profitability and a sound balance sheet over time. Better than 97% of Nordic stocks.

Value15

The price measured against earnings, assets and cash flow. Better than 15% of Nordic stocks.

Trend37

The price development over the past year. Better than 37% of Nordic stocks.

Combined45

Quality, value and trend together. Better than 45% of Nordic stocks.

About ALK-Abelló

ALK-Abelló A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 2,800 employees.

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis